This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04341298
Recruitment Status : Completed
First Posted : April 10, 2020
Results First Posted : January 9, 2023
Last Update Posted : January 9, 2023
Sponsor:
Collaborator:
Imarc Research, Inc.
Information provided by (Responsible Party):
Avulux, Inc.

Brief Summary:
The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application, when compared to a control device.

Condition or disease Intervention/treatment Phase
Migraine Other: 11-point pain scale Other: Headache diary Device: Avulux® Device: Sham Avulux® Not Applicable

Detailed Description:

Avulux® is intended to reduce the severity of headache pain in adult patients diagnosed with episodic migraine headaches. In this study, the investigative Avulux® device shall consist of a pair of optical filters in the form of spectacle lenses, provided in a standard spectacle frame; the lenses contain a dye that effectively blocks light at specified wavelength ranges while minimizing distortion of the visible spectrum. The optical filters block a portion of the optical spectrum that is suspected to stimulate photophobic responses that trigger some, and exacerbate most, migraines.

The control/sham device for this study shall be a pair of plastic lenses provided in a standard spectacle frame, which will have negligible light-blocking properties at the optical wavelengths which are blocked by the Avulux® device.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A minimum of 68 subjects will be randomized in to one of two treatment groups in a one-to-one ratio.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:

In this study, the investigative Avulux® device shall consist of a pair of optical filters in the form of spectacle lenses, provided in a standard spectacle frame; the lenses contain a dye that effectively blocks light at specified wavelength ranges while minimizing distortion of the visible spectrum. The optical filters block a portion of the optical spectrum that is suspected to stimulate photophobic responses that trigger some, and exacerbate most, migraines.

The control/sham device for this study shall be a pair of plastic lenses provided in a standard spectacle frame, which will have negligible light-blocking properties at the optical wavelengths which are blocked by the Avulux® device.

Primary Purpose: Treatment
Official Title: Clinical Evaluation of Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
Actual Study Start Date : April 6, 2020
Actual Primary Completion Date : August 26, 2020
Actual Study Completion Date : August 26, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
MedlinePlus related topics: Headache Migraine

Arm Intervention/treatment
Experimental: Avulux® device
Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
Other: 11-point pain scale
Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.

Other: Headache diary
Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.

Device: Avulux®
Avulux® device

Sham Comparator: Control/sham device
Subjects will be instructed to use the glasses for four weeks. They will be instructed to put the glasses on at the first signs or symptoms consistent with the onset of a migraine attack or at the first onset of aura and keep the glasses on until their headache has resolved.
Other: 11-point pain scale
Subjects will be asked to rate their headache pain using an 11-point scale, i.e. on an integer scale from 0 to 10 inclusive, with 0 indicating no pain and 10 indicating the worst pain imaginable.

Other: Headache diary
Subjects will be asked to record specific information for the first (and all subsequent) severe or very severe migraine headaches that they experience while enrolled in the study.

Device: Sham Avulux®
Sham Avulux®




Primary Outcome Measures :
  1. Change in 11-point Pain Scale Score After Two Hours (First Severe Headache) [ Time Frame: from baseline to 2 hours after device application ]
    Change in migraine pain from baseline to 2 hours after device application, based on first severe or very severe migraine headache experienced by a study subject (i.e. baseline pain score of 6 or higher). Pain scale is an 11-point scale, with integer values from 0 (no pain) to 10 (worst pain imaginable) inclusive.


Secondary Outcome Measures :
  1. Change in 11-point Pain Scale Score After Four Hours (First Severe Headache) [ Time Frame: from baseline to four hours after device application ]
    Change in migraine pain from baseline to 4 hours after device application, based on first severe or very severe migraine headache experienced by a study subject (i.e. baseline pain score of 6 or higher). Pain scale is an 11-point scale, with integer values from 0 (no pain) to 10 (worst pain imaginable) inclusive.


Other Outcome Measures:
  1. Number of Subjects With Quantifiable Improvement in Pain Score After Two Hours (First Severe Headache) [ Time Frame: from baseline to 2 hours after device application ]
    Number of subjects who show quantifiable improvement in overall migraine impact, as measured by a change in migraine pain from severe (i.e. baseline pain score of 6 or higher) to mild/no pain (defined as a pain score of 3 or less) after an elapsed time of 2 hours following application of the device, based on first severe or very severe migraine headache experienced by a study subject. Pain scale is an 11-point scale, with integer values from 0 (no pain) to 10 (worst pain imaginable) inclusive.

  2. Number of Subjects Who Require the Use of Abortive Medications (First Severe Headache) [ Time Frame: baseline to 8 hours after device application ]
    Number of subjects who require abortive headache medication (e.g. analgesic or triptan) to control their first severe or very severe migraine headache (i.e. baseline pain score of 6 or higher) within 8 hours following application of the device. Pain scale is an 11-point scale, with integer values from 0 (no pain) to 10 (worst pain imaginable) inclusive.

  3. Number of Subjects Suffering From Light Sensitivity After 2 Hours (First Severe Headache) [ Time Frame: 2 hours after device application ]
    Number of subjects suffering from light sensitivity after elapsed time of 2 hours following application of the device, based on first severe or very severe migraine headache experienced by a study subject (i.e. baseline pain score of 6 or higher). Pain scale is an 11-point scale, with integer values from 0 (no pain) to 10 (worst pain imaginable) inclusive.

  4. Number of Subjects Suffering From Light Sensitivity After 4 Hours (First Severe Headache) [ Time Frame: 4 hours after device application ]
    Number of subjects suffering from light sensitivity after elapsed time of 4 hours following application of the device, based on first severe or very severe migraine headache experienced by a study subject (i.e. baseline pain score of 6 or higher). Pain scale is an 11-point scale, with integer values from 0 (no pain) to 10 (worst pain imaginable) inclusive.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is 18 years or older
  • Subject is willing and able to provide written informed consent
  • Diagnosis of migraine, based on a history of at least 5 attacks per month with the following primary headache characteristics:

    • Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
    • Headache has at least two of the following characteristics:

      • unilateral location
      • pulsating quality
      • moderate or severe pain intensity
      • aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs)
    • Headache occurs with at least one of the following symptoms:

      • nausea and/or vomiting
      • photophobia and phonophobia
  • Subject has experienced at least 4 migraine attacks in the last month, with at least two migraine attacks resulting in severe pain prior to the use of any abortive medications
  • Migraines are not attributed to another disorder

Exclusion Criteria:

  • Subjects participating in another prospective, interventional clinical study
  • Subjects with other light sensitive conditions, such as iritis
  • Subjects who have less than 4 headache days per month with the above characteristics
  • Chronic migraine subjects (defined as subjects who experience a minimum of 15 headache days per month)
  • Subjects with headaches due to medication overuse (defined as regular use of headache medication for a minimum of 10 days per month, for a minimum period of 3 months)
  • Subjects who have had any change in their migraine treatment within 4 weeks prior to study enrollment
  • Subjects whose family members are currently participating in this study, or are employees of the study site, Avulux, or the coordinating CRO

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04341298


Locations
Layout table for location information
United States, Minnesota
Clinical Research Institute, Inc.
Minneapolis, Minnesota, United States, 55402
United States, Ohio
Endocrinology Research Associates, Inc.
Columbus, Ohio, United States, 43201
Remington-Davis Clinical Research
Columbus, Ohio, United States, 43215
Sponsors and Collaborators
Avulux, Inc.
Imarc Research, Inc.
  Study Documents (Full-Text)

Documents provided by Avulux, Inc.:
Layout table for additonal information
Responsible Party: Avulux, Inc.
ClinicalTrials.gov Identifier: NCT04341298    
Other Study ID Numbers: 20200480
First Posted: April 10, 2020    Key Record Dates
Results First Posted: January 9, 2023
Last Update Posted: January 9, 2023
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations